David Yeung

Adelaide Medical School
Faculty of Health and Medical Sciences

Connect With Me

David Yeung

Journals

Date Citation
2016 Parker,W, Yeung,D, Yeoman,A, Altamura,H, Jamison,B, Field,C, Hodgson,J, Lustgarten,S, Rivera,V, Hughes,T et al, 2016, The impact of multiple low-level BCR-ABL1 mutations on response to ponatinib, Blood, 127, 15, 1870-1880 10.1182/blood-2015-09-666214
2016 Nievergall,E, Reynolds,J, Kok,C, Watkins,D, Biondo,M, Busfield,S, Vairo,G, Fuller,K, Erber,W, Sadras,T et al, 2016, TGF-α and IL-6 plasma levels selectively identify CML patients who fail to achieve an early molecular response or progress in the first year of therapy, Leukemia, 30, 6, 1263-1272 10.1038/leu.2016.34
2015 Yeung,D, Osborn,M, White,D, Branford,S, Braley,J, Herschtal,A, Kornhauser,M, Issa,S, Hiwase,D, Hertzberg,M et al, 2015, TIDEL-Ii: first-line use of imatinib in CML with early switch to nilotinib for failure to achieve time-dependent molecular targets, Blood, 125, 6, 915-923 10.1182/blood-2014-07-590315
2015 Yeung,D, Moulton,D, Heatley,S, Nievergall,E, Dang,P, Braley,J, Branford,S, Moore,S, Mulligan,C, Hughes,T et al, 2015, Relapse of BCR-ABL1-like ALL mediated by the ABL1 kinase domain mutation T315I following initial response to dasatinib treatment, Leukemia, 29, 1, 230-232 10.1038/leu.2014.256
2015 Yeung,D, Tang,C, Vidovic,L, White,D, Branford,S, Hughes,T, Yong,A, 2015, KIR2DL5B genotype predicts outcomes in CML patients treated with response-directed sequential imatinib/nilotinib strategy, Blood, 126, 25, 2720-2723 10.1182/blood-2015-07-655589
2014 Branford,S, Yeung,D, Parker,W, Roberts,N, Purins,L, Braley,J, Altamura,H, Yeoman,A, Georgievski,J, Jamison,B et al, 2014, Prognosis for patients with CML and >10% BCR-ABL1 after 3 months of imatinib depends on the rate of BCR-ABL1 decline, Blood, 124, 4, 511-518 10.1182/blood-2014-03-566323
2014 Parker,W, Phillis,S, Yeung,D, Hughes,T, Scott,H, Branford,S, 2014, Many BCR-ABL1 compound mutations reported in chronic myeloid leukemia patients may actually be artifacts due to PCR-mediated recombination, Blood, 124, 1, 153-155 10.1182/blood-2014-05-573485
2014 Yeung,D, Mauro,M, 2014, Prognostic significance of early molecular response in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors, Hematology, 2014, 1, 240-243 10.1182/asheducation-2014.1.240
2013 Vandyke,K, Fitter,S, Drew,J, Fukumoto,S, Schultz,C, Sims,N, Yeung,D, Hughes,T, Zannettino,A, 2013, Prospective histomorphometric and DXA evaluation of bone remodeling in imatinib-treated CML patients: Evidence for site-specific skeletal effects, Journal of Clinical Endocrinology and Metabolism, 98, 1, 67-76 10.1210/jc.2012-2426
2013 Parker,W, Yeoman,A, Jamison,B, Yeung,D, Scott,H, Hughes,T, Branford,S, 2013, BCR-ABL1 kinase domain mutations may persist at very low levels for many years and lead to subsequent TKI resistance, British Journal of Cancer, 109, 6, 1593-1598 10.1038/bjc.2013.318
2013 Ross,D, Branford,S, Seymour,J, Schwarer,A, Arthur,C, Yeung,D, Dang,P, Goyne,J, Slader,C, Filshie,R et al, 2013, Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study, Blood, 122, 4, 515-522 10.1182/blood-2013-02-483750
2013 Branford,S, Yeung,D, Ross,D, Prime,J, Field,C, Altamura,H, Yeoman,A, Georgievski,J, Jamison,B, Phillis,S et al, 2013, Early molecular response and female sex strongly predict stable undetectable BCR-ABL1, the criteria for imatinib discontinuation in patients with CML, Blood, 121, 19, 3818-3824 10.1182/blood-2012-10-462291
2012 Yeung,D, Branford,S, 2012, Monitoring disease response in chronic-phase chronic myeloid leukemia: the age of molecular assays?, Hematology, the Education Program of the American Society of Hematology. American Society of Hematology. Education Program, 2012, 1, 111-114 10.1182/asheducation-2012.1.111
2012 Yeung,D, Hughes,T, 2012, Therapeutic targeting of BCR-ABL: prognostic markers of response and resistance mechanism in chronic myeloid leukaemia, Critical Reviews in Oncogenesis, 17, 1, 17-30 10.1615/critrevoncog.v17.i1.30
2012 Branford,S, Yeung,D, Prime,J, Choi,S, Bang,J, Park,J, Kim,D, Ross,D, Hughes,T, 2012, BCR-ABL1 doubling times more reliably assess the dynamics of CML relapse compared with the BCR-ABL1 fold rise: implications for monitoring and management, Blood, 119, 18, 4264-4271 10.1182/blood-2011-11-393041
2011 Hiwase,D, Yeung,D, White,D, 2011, Optimizing the selection of kinase inhibitors for chronic myeloid leukemia patients, Expert Review of Hematology, 4, 3, 285-299 10.1586/ehm.11.19
2011 Yeung,D, Parker,W, Branford,S, 2011, Molecular methods in diagnosis and monitoring of haematological malignancies, Pathology, 43, 6, 566-579 10.1097/PAT.0b013e32834a9da8
2011 Yeung,D, White,D, 2011, Imatinib trough levels in chronic myelogenous leukemia: does one dose fit all?, Leukemia and Lymphoma, 52, 2, 165-167 10.3109/10428194.2010.540362

Book Chapters

Date Citation
2016 Yeung,DT, Branford,S, 2016, Optimal monitoring of CML treatment: Molecular and mutation analysis, Springer, Japan, pp. 101-129 10.1007/978-4-431-55714-2_7

Conference Papers

Date Citation
2015 Singhal,D, Hague,S, Roxby,D, Wee,LA, Lee,O-L, Sinha,R, Chhetri,R, Gray,JX, Giri,P, Robinson,K et al, 2015, RBC Alloimmunization Burden Is High in Regularly RBC-Transfused Myelodysplastic Syndrome (MDS) Patients: A Report from South Australian-MDS Registry, 57th Annual Meeting of the American-Society-of-Hematology, Orlando, FL
2015 Hughes,TP, Cervantes,F, Leber,B, Spector,N, Lipton,JH, Pasquini,R, Clementino,NCD, Schwarer,AP, Mahon,FX, Rea,D et al, 2015, ENESTCMR 4-Y RESULTS: PATIENTS (PTS) WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML-CP) AND RESIDUAL DISEASE MORE LIKELY TO ACHIEVE DEEP MOLECULAR RESPONSE FOLLOWING SWITCH TO NILOTINIB (NIL), 20th Congress of European-Hematology-Association, Vienna, AUSTRIA
2015 Kok,CH, Leclercq,TM, Watkins,D, Yeung,DT, Saunders,VA, White,DL, Hughes,TP, 2015, A 20 Gene Expression Signature That Predicts Early Molecular Response Failure in Chronic Phase CML Patients Treated with Frontline Imatinib, 57th Annual Meeting of the American-Society-of-Hematology, Orlando, FL
2015 Yeung,DT, Parker,WT, Phillis,S, Georgievski,J, Scott,HS, Hughes,TP, Branford,S, 2015, BCR-ABL Assay Sensitivity of MR4.5 Achieved in >90%, and MR5 in >75% of Samples, through mRNA Selection before qRT-PCR, 57th Annual Meeting of the American-Society-of-Hematology, Orlando, FL
2015 Marum,JE, Purins,L, Yeung,DT, Parker,WT, Price,DJ, Wang,PP, Stangl,D, Geogievski,J, Chereda,B, Schreiber,A et al, 2015, Germline Genetic Variation of ASXL1 and BIM Predicts Response to Imatinib and Identifies a Subset of High Sokal Risk Patients with the Greatest Risk of Treatment Failure and Disease Progression, 57th Annual Meeting of the American-Society-of-Hematology, Orlando, FL
2011 Branford,S, Yeung,DT, Prime,J, Ross,D, Hughes,TP, 2011, Imatinib Dose Interruption in Responding CML Patients Is Associated with Characteristic BCR-ABL Kinetics, Which Could Help to Differentiate Non-Adherence From Drug Resistance, 53rd Annual Meeting and Exposition of the American-Society-of-Hematology (ASH)/Symposium on the Basic Science of Hemostasis and Thrombosis, San Diego, CA
2011 White,DL, Saunders,VA, Frede,A, GrootObbink,K, Slader,C, Yeung,DT, Osborn,M, Mills,AK, Grigg,A, Hughes,TP et al, 2011, The Strategy of Early Nilotinib Switch Based on Failure to Achieve Optimal Molecular Targets on Imatinib May Not Overcome the Negative Impact of a Low OCT-1 Activity in De-Novo CP-CML Patients, 53rd Annual Meeting and Exposition of the American-Society-of-Hematology (ASH)/Symposium on the Basic Science of Hemostasis and Thrombosis, San Diego, CA
2011 Yeung,DT, Osborn,M, White,DL, Branford,S, Kornhauser,M, Slader,C, Issa,S, Hiwase,DK, Hertzberg,MS, Schwarer,AP et al, 2011, Upfront Imatinib Therapy in CML Patients with Rapid Switching to Nilotinib for Failure to Achieve Molecular Targets or Intolerance Achieves High Overall Rates of Molecular Response and a Low Risk of Progression - An Update of the TIDEL-II Trial, 53rd Annual Meeting and Exposition of the American-Society-of-Hematology (ASH)/Symposium on the Basic Science of Hemostasis and Thrombosis, San Diego, CA
2011 Hughes,TP, Lipton,JH, Leber,B, Spector,N, Cervantes,F, Pasquini,R, Clementino,N, Schwarer,AP, Mahon,FX, Rea,D et al, 2011, Complete Molecular Response (CMR) Rate with Nilotinib in Patients (pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) without CMR, After >= 2 Years on Imatinib: Preliminary Results From the Randomized ENESTcmr Trial of Nilotinib 400 Mg Twice Daily (BID) Vs Imatinib, 53rd Annual Meeting and Exposition of the American-Society-of-Hematology (ASH)/Symposium on the Basic Science of Hemostasis and Thrombosis, San Diego, CA
2010 White,DL, Saunders,V, Andrew,M, Rofe,A, Slader,C, Yeung,DT, Osborn,M, Mills,AK, Grigg,A, Hughes,T et al, 2010, Imatinib PK: Observations From the TIDEL II Study., 52nd Annual Meeting of the American-Society-of-Hematology (ASH), Orlando, FL
2010 Yeung,D, Osborn,M, White,D, Branford,S, Haswell,L, Slader,C, Issa,S, Hiwase,D, Hertzberg,M, Schwarer,A et al, 2010, Selective escalation of imatinib therapy and early switching to nilotinib in de novo chronic phase CML patients: interim results from the TIDELL-II trial, American Society of Hematology conference, Florida
2010 Yeung,DT, Osborn,M, White,DL, Branford,S, Haswell,L, Slader,C, Issa,S, Hiwase,DK, Hertzberg,MS, Schwarer,AP et al, 2010, Selective Escalation of Imatinib Therapy and Early Switching to Nilotinib In De Novo Chronic Phase CML Patients: Interim Results From the TIDEL-II Trial, 52nd Annual Meeting of the American-Society-of-Hematology (ASH), Orlando, FL
2010 White,DL, Saunders,V, Frede,A, GrootObbink,K, Slader,C, Yeung,DT, Osborn,M, Mills,AK, Grigg,A, Hughes,T et al, 2010, Early Switching From Imatinib to Nilotinib In CML Patients Failing to Achieve Early Molecular Targets May Not Be An Effective Approach In Patients with Very Low OCT-1 Activity: A TIDEL II Sub-Study, 52nd Annual Meeting of the American-Society-of-Hematology (ASH), Orlando, FL

Conference Items

Date Citation
2014 Branford,S, Ross,D, Yeung,D, Braley,J, Hughes,T, 2014, Achieving the deep molecular response levels required for an imatinib discontinuation trial is strongly associated with the BCR-ABL level at the first qualifying timepoint, 56th ASH Annual Meeting, San Francisco, California
2014 Yeung,DT, Vidovic,L, Tang,C, White,DL, Branford,S, Hughes,TP, Yong,AS, 2014, KIR2DL5B Genotype Independently Predicts Poor Outcomes in CML-CP Patients Switched to Nilotinib after Suboptimal Responses to Imatinib and May Refine Prognosis in Patients with EMR Failure, 56th Annual Meeting of the American-Society-of-Hematology, San Francisco, CA
2014 Branford,S, Yeung,D, Ross,D, Parker,W, Braley,J, Seymour,J, Hughes,T, 2014, The adverse effect of high sokal risk for first line imatinib treated patients is overcome by a rapid rate of BCR-ABL decline measured as early as 1 month of treatment, 56th ASH Annual Meeting, San Francisco, California
2014 Parker,WT, Phillis,SR, Yeung,DT, Lawrence,D, Schreiber,A, Wang,P, Geoghegan,J, Lustgarten,S, Hodgson,G, Rivera,VM et al, 2014, Detection of BCR-ABL1 Compound and Polyclonal Mutants in Chronic Myeloid Leukemia Patients Using a Novel Next Generation Sequencing Approach That Minimises PCR and Sequencing Errors, 56th Annual Meeting of the American-Society-of-Hematology, San Francisco, CA
2014 Nievergall,E, Reynolds,J, Kok,CH, Watkins,D, Biondo,M, Busfield,SJ, Vairo,G, Yeung,DT, Lopez,A, Hiwase,DK et al, 2014, High plasma levels of TGF-α and IL-6 at diagnosis predict early molecular response failure and transformation in CML, 56th ASH Annual Meeting, San Francisco, California
2013 Parker,W, Yeoman,A, Altamura,H, Roberts,N, Yeung,D, Jamison,B, Field,C, Lustgarten,S, Hodgson,G, Rivera,V et al, 2013, Additional BCR-ABL1 Mutations Identified By Sensitive Mass Spectrometry In Chronic Phase CML Patients With T315I Treated With Ponatinib Are Associated With Relatively Inferior Responses and Outcome
2013 Hiwase,D, Yeung,D, Carne,L, Ross,D, Grigg,A, Hughes,T, 2013, Hypercholesterolemia In Imatinib Intolerant/Resistant CML-CP Patients Treated With Nilotinib: A Retrospective Analysis
2013 Parker,W, Phillis,S, Yeung,D, Hughes,T, Scott,H, Branford,S, 2013, PCR-mediated recombination can lead to artificial chimera formation, which may pose as BCR-ABL1 compound mutations, 55th American Society of Hematology Annual Meeting and Exhibition, New Orleans, Louisiana
2012 Parker,WT, Yeoman,AL, Jamison,BA, Yeung,DT, Scott,HS, Hughes,TP, Branford,S, 2012, The patient's BCR-ABL1 Kinase Domain Mutation History Is Important for Decisions Regarding Tyrosine Kinase Inhibitor Therapy, 54th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH), Atlanta, GA
2012 Branford,S, Ross,D, Prime,J, Field,C, Altamura,H, Yeoman,A, Georgievski,J, Phillis,S, Jamison,BA, Sullivan,B et al, 2012, Early Molecular Response and Female Sex Strongly Predict Achievement of Stable Undetectable BCR-ABL1, a Criterion for Imatinib Discontinuation in Patients with CML, 54th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH), Atlanta, GA
2012 Yeung,DT, Osborn,MP, White,DL, Branford,S, Kornhauser,M, Slader,C, Issa,S, Hiwase,DK, Hertzberg,MS, Schwarer,AP et al, 2012, Early Switch to Nilotinib Does Not Overcome the Adverse Outcome for CML Patients Failing to Achieve Early Molecular Response On Imatinib, Despite Excellent Overall Outcomes in the TIDEL II Trial, 54th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH), Atlanta, GA
Org Unit
Medical Specialties

top